Pfizer - JAK Inhibitors in RA: What, Where, How, Why, Who and When?


Industry room 1
English
Satellite Symposia
02 June 2021 18:15 - 19:45

Learning Objectives: 

 

  • To examine the place of JAK inhibitors in the rheumatoid arthritis (RA) treatment paradigm
  • To discuss the rationale for selecting JAK inhibitors as a treatment option in RA based on an assessment of the benefits and risks as well as patient preferences and patient-reported outcomes 
  • To evaluate the data available in subgroup populations that support informed discussions around safety and efficacy of JAK inhibitors in RA, and how these can be communicated to patients

Presentations

Title Time Calendar .ics
Welcome and Faculty Introductions
02 June 2021 18:15 - 18:20 .ics
The Rationale for Selecting JAK Inhibitors as a Treatment Option in RA
02 June 2021 18:20 - 18:40 .ics
What Have We Learned About JAK Inhibitors in RA?
02 June 2021 18:40 - 19:10 .ics
Where Do JAK Inhibitors Fit Into the RA Treatment Paradigm?
02 June 2021 19:10 - 19:25 .ics
Faculty Discussion and Q&A
02 June 2021 19:25 - 19:40 .ics
Summary and Close
02 June 2021 19:40 - 19:45 .ics